Per that information, Louisiana is currently excluded
The body adapts to specific receptor activation patterns, and changing medications creates a transition period that requires planning
Eli Lilly and Novo Nordisk have had multiple FDA-approved GLP-1 drugs on the market since 2022, though record-high demand, chronic supply shortages and pricing concerns have created challenges for the drugmakers
Rather than jumping to the maximum dose as quickly as the prescribing guidelines allow, consider staying at each dose level for a longer period
Despite GLPs actions on lowering appetite, dysregulated food relationships or food addiction can overpower this and lead us to overeat
Recommended for: tirzepatide patients optimizing for cost, patients pursuing maximal fat oxidation support, patients with no specific methylation concerns